Share ownership Intellia Therapeutics, Inc.

NTLA

US45826J1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:23:41 2026-04-13 am EDT			5-day change	1st Jan Change
13.68 ^USD	+1.37%		+2.33%	+51.39%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

Share class: Intellia Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	101,848,572	100,351,139 ( 98.53 %)	0	98.53 %

Major shareholders: Intellia Therapeutics, Inc.

Name	Equities	%	Valuation
ARK Investment Management LLC 12.27 %	14,207,324	12.27 %	196 M $
Vanguard Fiduciary Trust Co. 11.23 %	13,010,001	11.23 %	179 M $
BlackRock Advisors LLC 8.26 %	9,567,064	8.26 %	132 M $
STATE STREET CORPORATION 5.542 %	6,418,836	5.542 %	88 M $
D.E. Shaw & Co., Inc. 4.602 %	5,331,064	4.602 %	73 M $
REGENERON PHARMACEUTICALS, INC. 3.197 %	3,702,995	3.197 %	51 M $
Two Sigma Investments LP 2.33 %	2,698,738	2.33 %	37 M $
Geode Capital Management LLC 2.328 %	2,696,187	2.328 %	37 M $
Two Sigma Advisers LP 2.026 %	2,346,317	2.026 %	32 M $
Morgan Stanley Capital Services LLC 2.01 %	2,327,852	2.01 %	32 M $
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	68.37%
Other	11.84%
State Street Corp.	5.54%
Regeneron Pharmaceuticals, Inc.	3.2%
Individuals	2.22%
Schweizerische Nationalbank	0.17%
SEI Investments Co.	0.06%
Manulife Financial Corp.	0.04%
Unknown	8.56%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	78.41%
United Kingdom	5.06%
Individuals	2.22%
Australia	1.6%
Ireland	0.71%
Bermuda	0.62%
Switzerland	0.6%
Singapore	0.5%
Canada	0.34%
France	0.3%
China	0.29%
Germany	0.23%
Denmark	0.17%
Cayman Islands	0.12%
Spain	0.06%
Japan	0.04%
Puerto Rico	0.04%
Sweden	0.03%
Poland	0.03%
South Africa	0.02%
Norway	0.02%
Hong Kong	0.02%
Belgium	0.01%

Based on 1000 largest holdings

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Employees

377

Sector

Biotechnology & Medical Research

More about the company